Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...
An Instagram post by nutritional endocrinologist Dr Shanti has reignited conversations around the risks of self-prescribing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results